Trial-Results center  
Clinical trial results database 100 Feedback    Home


Related trials

BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent

SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent

SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent

RESOLUTE, 2010 - zotarolimus eluting stent vs everolimus eluting stent

ISAR-DESIRE-2, 2010 - sirolimus eluting stent vs paclitaxel eluting stent

GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent

BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent

PASEO, 2009 - drug-eluting stents vs bare-metal stent

SYNTAX, 2009 - paclitaxel eluting stent vs CABG

ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent

COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent

ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

BARI 2D, 2009 - CABG or PCI vs medical treatment

DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent

ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent

ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent

ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis



See also:

  • All acute myocardial infarction clinical trials
  • All coronary artery disease clinical trials
  • All stable angina clinical trials
  • All clinical trials of PCI
  • All clinical trials of sirolimus eluting stent
    		•  

    Di Lorenzo et al. study, 2005

    unpublished (or not yet fully published) trial Facebook    pdf : sirolimus eluting stent - myocardial revascularization for stable angina

    Treatments

    Studied treatment sirolimus
    Control treatment paclitaxel

    Patients

    Patients ST-segment elevation myocardial infarction

    Method and design

    Randomized effectives 90 / 90 (studied vs. control)
    Design Parallel groups
    Blinding open
    Number of centre NA
    Geographic area NA


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    3 / 90
         4 / 90
         classic 0,75 [0,17;3,26]

    MI (fatal and non fatal)

    4 / 90
         3 / 90
         classic 1,33 [0,31;5,79]

    target lesion revascularisation

    3 / 90
         4 / 90
         classic 0,75 [0,17;3,26]

    angiographic restenosis

    NA / 90
         NA / 90

    4y stent thrombosis (ARC)

    0 / 90
         1 / 90
         classic 0,20 [0,00;14,51]

    Stent thrombosis (any, end of follow up)

    0 / 90
         1 / 90
         classic 0,20 [0,00;14,51]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 3 / 90 (3,3%) 4 / 90 (4,4%) 0,75 [0,17;3,26]    
    MI (fatal and non fatal) 4 / 90 (4,4%) 3 / 90 (3,3%) 1,33 [0,31;5,79]    
    target lesion revascularisation 3 / 90 (3,3%) 4 / 90 (4,4%) 0,75 [0,17;3,26]    
    4y stent thrombosis (ARC) 0 / 90 (0,6%) 1 / 90 (1,1%) 0,50 [0,02;14,72]    
    Stent thrombosis (any, end of follow up) 0 / 90 (0,6%) 1 / 90 (1,1%) 0,50 [0,02;14,72]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 3,33% 4,44% -11,1‰
    MI (fatal and non fatal) 4,44% 3,33% 1,1%
    target lesion revascularisation 3,33% 4,44% -11,1‰

    Meta-analysis of all similar trials:

    Drug eluting stent in coronary artery disease for all type of patients

    myocardial revascularization in acute myocardial infarction for all type of patients

    myocardial revascularization in coronary artery disease for all type of patient

    myocardial revascularization in stable angina for all type of patient

    PCI in acute myocardial infarction for all type of patients



    Reference(s)

    Trials register # NA

    unpublished (or not yet fully published) trial

    • Di Lorenzo E, Varricchio A, Lanzillo T, et al.. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr). Circulation 2005;112:U538
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend